Yulizar D.R. and Sunarjo Hardjowijoto, NIDN. 9900981294 and Wahjoe Djatisoesanto, NIDN. 8826900016 and Soemarno T. (2008) Difference in cyclooxygenase-2 (cox-2) expression between low and high grade papillary carcinoma in human bladder cancer. Folia Medica Indonesiana, 44 (02). pp. 71-75. ISSN 0303-7932

	Text (Peer Review) Dufference in Cyclooxygenase-2.pdf Download (2MB)
	Text (Artikel) Difference in Cyclooxygenase-2 (COX-2) Expression Between Low And High Grade Papillary Carcinoma In Human Bladder Cancer.pdf Download (248kB)
	Text (Similarity) Difference in Cyclooxygenase-2 (COX-2) Expression Between Low And High Grade Papillary Carcinoma In Human Bladder Cancer (1).pdf Download (2MB)

Abstract

The objective of this study was to improve the estimation of the prognostic behavior by difference of cyclooxygenase-2 (COX-2) expression between low and high grade papillary carcinoma of human transitional cell bladder cancer. We used COX-2 expression as a parameter for prognostic behavior. It was studied by immunohistochemical methods in 36 samples of human transitional cell carcinoma of the bladder from pathology archive. COX-2 immunostaining identifies intracytoplasmic content of COX-2 in human bladder cancer cell, measured by scale of staining which is scored 0 (0-9.9%), 1 (10-49.9%), 2 (50-99.9%) and scale of immunostaining intensity which was scored 0 (negative), 1+ (weak), 2+ (strong). The results of this study revealed that COX-2 immunostaining identified 19 high grade papillary carcinoma (16 samples were 2+(strong), 2 samples were 1+(weak), and 1 sample was 0 (negative) and 17 low grade papillary carcinoma (9 samples were 2+(strong), 3 samples were 1+(weak), and 5 samples were 0 (negative). There was a distribution difference in COX-2 expression between low grade and high grade papillary carcinoma (p = 0.035) analyzed by the Mann-Whitney test, favoring more strong of COX-2 expression in high grade tumor than expected with equal distribution. In conclusions, these findings suggest that the difference in COX-2 expression in may be used as an additional biomarker of its progressiveness.

Actions (login required)

View Item